BASF Plans to “Ramp Up” Spending in Diagnostic Medicines

BASF plans to “ramp up” spending to develop diagnostic and prognostic test products that have been designed by its human health biotech business Metanomics Health (Berlin), Peter Oakley, BASF board member responsible for Agricultural Products and Fine Chemicals, told journalists at a briefing in Berlin this week. The company is developing novel diagnostic tests including those that could predict the onset of certain diseases in people, such as diabetes, potentially enabling physicians to prevent the onset of a given disease in the first place. The...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers